Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This m...
Saved in:
Main Author: | |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_4be9a7574ba34e8082fc0e2d31f36784 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Kristof Chwalisz, M.D., Ph.D. |e author |
245 | 0 | 0 | |a Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
260 | |b Elsevier, |c 2023-06-01T00:00:00Z. | ||
500 | |a 2666-3341 | ||
500 | |a 10.1016/j.xfre.2023.02.002 | ||
520 | |a Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This mini review aims to summarize the key clinical studies that led to its regulatory approval. | ||
546 | |a EN | ||
690 | |a Elagolix | ||
690 | |a GnRH antagonist | ||
690 | |a endometriosis | ||
690 | |a uterine fibroids | ||
690 | |a Diseases of the genitourinary system. Urology | ||
690 | |a RC870-923 | ||
690 | |a Gynecology and obstetrics | ||
690 | |a RG1-991 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n F&S Reports, Vol 4, Iss 2, Pp 65-72 (2023) | |
787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S2666334123000107 | |
787 | 0 | |n https://doaj.org/toc/2666-3341 | |
856 | 4 | 1 | |u https://doaj.org/article/4be9a7574ba34e8082fc0e2d31f36784 |z Connect to this object online. |